U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07025564) titled 'MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia' on June 06.
Brief Summary: This phase I trial tests the safety, side effects, and best dose of miRisten in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). MiRisten may stop the growth of cancer cells by blocking some of the molecules needed for cell growth. Giving miRisten may be safe, tolerable and/or effective in treating patients with relapsed or refractory AML.
Study Start Date: Feb. 28, 2026
Study Type: INTERVENTIONAL
Conditi...